argenx SE reported $417M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AstraZeneca USD 5.8B 735M Jun/2026
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.19B 75M Jun/2026
GRIFOLS EUR 289M 8M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Qiagen NV USD 142.39M 11.49M Mar/2026
UCB EUR 1.47B 193M Dec/2025